CD274 and glioblastoma: Although there are many ongoing clinical trials exploring the efficacy of PD-1/PD-L1 blockades like pembrolizumab and nivolumab in primary or recurrent GBM, breakthroughs have not been achieved in improving prognosis due to the relatively immunosuppressive TME in central nervous system (6).